Market Research Logo

Urinary Incontinence - Pipeline Review, H2 2015

Urinary Incontinence - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Urinary Incontinence - Pipeline Review, H2 2015’, provides an overview of the Urinary Incontinence’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Urinary Incontinence, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Urinary Incontinence and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Urinary Incontinence
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Urinary Incontinence and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Urinary Incontinence products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Urinary Incontinence pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Urinary Incontinence
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Urinary Incontinence pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Urinary Incontinence Overview
Therapeutics Development
Pipeline Products for Urinary Incontinence - Overview
Pipeline Products for Urinary Incontinence - Comparative Analysis
Urinary Incontinence - Therapeutics under Development by Companies
Urinary Incontinence - Therapeutics under Investigation by Universities/Institutes
Urinary Incontinence - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Urinary Incontinence - Products under Development by Companies
Urinary Incontinence - Products under Investigation by Universities/Institutes
Urinary Incontinence - Companies Involved in Therapeutics Development
Allergan Plc
Astellas Pharma Inc.
Celogos
Cook MyoSite Incorporated
Evotec AG
FemmePharma Global Healthcare, Inc.
Innovacell Biotechnologie AG
TheraVida, Inc.
Urinary Incontinence - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(mirabegron + solifenacin succinate) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ASP-2205 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ASP-5633 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cell Therapy for Urinary Incontinence - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ICES-13 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
oxybutynin hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Prof-003 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RCD-1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
senrebotase - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Antagonize P2X3 and P2X2/3 for Inflammatory Pain, Neuropathic Pain and Urinary Incontinence - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Stem Cell Therapy for Fecal Incontinence, Ischemic Heart Failure and Urological Diseases - Drug Profile
Product Description
Mechanism of Action
R&D Progress
THVD-201 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
THVD-202 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Urinary Incontinence - Recent Pipeline Updates
Urinary Incontinence - Dormant Projects
Urinary Incontinence - Discontinued Products
Urinary Incontinence - Product Development Milestones
Featured News & Press Releases
May 17, 2015: Mirabegron As Add-On Treatment To Solifenacin Therapy Demonstrated Superior Results To Solifenacin Monotherapy In BESIDE Trial
Jul 03, 2013: Impax Laboratories Confirms Patent Challenge Relating to Generic TOVIAZ 4 mg and 8 mg
Jan 03, 2013: TheraVida Announces Positive Top-line Phase II Results For Tolenix In Patients With Overactive Bladder And Urge Urinary Incontinence
Mar 15, 2012: Innovacell To Present Phase IIb Trial Results Of ICES13 At MedTech Investing Europe Conference
Dec 05, 2011: Pfizer’s Toviaz Shows Positive Top-Line Primary Endpoint Result In Study Of Overactive Bladder In Vulnerable Elderly Patients
Nov 08, 2011: Pfizer Announces Positive Top-Line Primary Endpoint Results Of Toviaz In Overactive Bladder Including Nocturnal Urinary Urgency
Aug 30, 2011: Innovacell passes a further milestone
May 16, 2011: TheraVida Initiates Phase II Trial Of THVD-201 For Overactive Bladder And Urinary Incontinence
Mar 22, 2011: TheraVida Announces Positive Results From Phase I Trial Of THVD-201
Feb 22, 2011: Innovacell makes further progress on product development
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Urinary Incontinence, H2 2015
Number of Products under Development for Urinary Incontinence - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Investigation by Universities/Institutes, H2 2015
Urinary Incontinence - Pipeline by Allergan Plc, H2 2015
Urinary Incontinence - Pipeline by Astellas Pharma Inc., H2 2015
Urinary Incontinence - Pipeline by Celogos, H2 2015
Urinary Incontinence - Pipeline by Cook MyoSite Incorporated, H2 2015
Urinary Incontinence - Pipeline by Evotec AG, H2 2015
Urinary Incontinence - Pipeline by FemmePharma Global Healthcare, Inc., H2 2015
Urinary Incontinence - Pipeline by Innovacell Biotechnologie AG, H2 2015
Urinary Incontinence - Pipeline by TheraVida, Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Urinary Incontinence Therapeutics - Recent Pipeline Updates, H2 2015
Urinary Incontinence - Dormant Projects, H2 2015
Urinary Incontinence - Dormant Projects (Contd..1), H2 2015
Urinary Incontinence - Dormant Projects (Contd..2), H2 2015
Urinary Incontinence - Discontinued Products, H2 2015
Urinary Incontinence - Discontinued Products (Contd..1), H2 2015
List of Figures
Number of Products under Development for Urinary Incontinence, H2 2015
Number of Products under Development for Urinary Incontinence - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report